Clinical Trials Logo

Wet Macular Degeneration clinical trials

View clinical trials related to Wet Macular Degeneration.

Filter by:

NCT ID: NCT05604989 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Associations Between the Oral and Intestinal Icrobiome and Neovascular Age-related Macular Degeneration

Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

A pilot study for Associations between the oral and intestinal microbiome and neovascular age-related macular degeneration and the investigation on the effect of oral probiotics as a treatment The investigators recruit the neovascular AMD patients and control patients. 1. 15 neovascular AMD patients with anti-VEGF treatment and oral probiotics supplement 2. 15 neovascular AMD patients with anti-VEGF treatment and no oral probiotics supplement 3. 15 control patients and no oral probiotics supplement The investigators will collect stool, blood, and saliva sample at the baseline and 6 months, and analyze the oral and intestinal microbiome changes.

NCT ID: NCT05562947 Recruiting - Clinical trials for Neovascular Age Related Macular Degeneration

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Start date: June 28, 2024
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.

NCT ID: NCT05461339 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration

nAMD
Start date: June 28, 2022
Phase: Phase 3
Study type: Interventional

This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).

NCT ID: NCT05456828 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

Start date: February 20, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the Phase 1 study is comprised of single ascending-dose component (Part 1) and multiple ascending-dose component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in patients with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT05345769 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Safety and Efficacy of AM712 in Patients With nAMD

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).

NCT ID: NCT05099094 Recruiting - Clinical trials for Diabetic Macular Edema

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

Start date: November 25, 2021
Phase: Early Phase 1
Study type: Interventional

Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).

NCT ID: NCT05093374 Recruiting - Clinical trials for Exudative Macular Degeneration

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).

NCT ID: NCT04853251 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

A Study Assessing Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)

Belvedere
Start date: December 14, 2021
Phase: Phase 4
Study type: Interventional

This study will assess corneal endothelial cells in patients with neovascular age-related macular degeneration (nAMD) treated with Port Delivery System with ranibizumab (PDS) refilled every 24 weeks (Q24W)

NCT ID: NCT04757610 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

ShORe
Start date: March 12, 2021
Phase: Phase 3
Study type: Interventional

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

NCT ID: NCT04690556 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD

Start date: September 14, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).